Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Ellis, T. Articles by Growdon, J. H. Search for Related Content PubMed Citation Articles by Ellis, T. Articles by Growdon, J. H. Parkinson's Disease

Clozapine and Risperidone Treatment of Psychosis in Parkinson's Disease

Received August 27, 1999; revised February 1, 2000; accepted February 7, 2000. From the Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts. Address correspondence to Dr. Cudkowicz, Massachusetts General Hospital, Department of Neurology, Room ACC 836, 32 Blossom Street, Boston, MA 02114.

The authors compared efficacy and safety of risperidone and clozapine for the treatment of psychosis in a double-blind trial with 10 subjects with Parkinson's disease (PD) and psychosis. Mean improvement in the Brief Psychiatric Rating Scale psychosis score was similar in the clozapine and the risperidone groups (P=0.23). Although the mean motor Unified Parkinson's Disease Rating Scale score worsened in the risperidone group and improved in the clozapine group, this difference did not reach statistical significance. One subject on clozapine developed neutropenia. In subjects with PD, risperidone may be considered as an alternative to clozapine because it is as effective for the treatment of psychoses without the hematologic, antimuscarinic, and seizure side effects. However, risperidone may worsen extrapyramidal symptoms more than clozapine and therefore must be used with caution.

Key Words: Parkinson's Disease • Clozapine • Risperidone

This article has been cited by other articles:

				U. Lertxundi, J. Peral, O. Mora, S. Domingo-Echaburu, M. J. Martinez-Bengoechea, and J. C. Garcia-Monco Antidopaminergic therapy for managing comorbidities in patients with Parkinson's disease Am. J. Health Syst. Pharm., March 1, 2008; 65(5): 414 - 419. [Abstract] [Full Text] [PDF]

				D. Weintraub and H. I. Hurtig Presentation and Management of Psychosis in Parkinson's Disease and Dementia With Lewy Bodies Am J Psychiatry, October 1, 2007; 164(10): 1491 - 1498. [Full Text] [PDF]

				M. Samuel, I. Maidment, M. Boustani, and C. Fox Clinical management of Parkinson's disease dementia: pitfalls and progress Advan. Psychiatr. Treat., March 1, 2006; 12(2): 121 - 129. [Abstract] [Full Text] [PDF]

				M. S. Ismail and I. H. Richard A Reality Test: How Well Do We Understand Psychosis in Parkinson's Disease? J Neuropsychiatry Clin Neurosci, February 1, 2004; 16(1): 8 - 18. [Abstract] [Full Text] [PDF]

				S. A. Factor, P. J. Feustel, J. H. Friedman, C. L. Comella, C. G. Goetz, R. Kurlan, M. Parsa, R. Pfeiffer, and the Parkinson Study Group Longitudinal outcome of Parkinson's disease patients with psychosis Neurology, June 10, 2003; 60(11): 1756 - 1761. [Abstract] [Full Text] [PDF]

				E. Mohr, K. Hildebrand, T. Mendis, P. P. De Deyn, I. H. Richard, and J. Nutt Worsening of motor function in Parkinson's disease: A "typical" response to "atypical" antipsychotic medications Neurology, May 8, 2001; 56(9): 1249 - 1250. [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2000 American Neuropsychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us